Affiliation:
1. Myasnikov Clinical Cardiology Institute, Federal State Budgetary Institution “National Medical Research Center of Cardiology” of the Ministry of Health of the Russian Federation
Abstract
The paper presents the clinical discussion of a patient with atrial fibrillation, who underwent a planned percutaneous coronary intervention. It also provides the recommendations for modern principles in diagnosis, the choice of optimal antithrombotic therapy in this pathology.
Reference17 articles.
1. 2018 ESC/EACTS Guidelines on myocardial revascularization European Heart Journal. 2018; 00: 1–96.
2. Angiolillo D. J., Goodmans. G., Bhatt D. L. et al. Antithrombotic therapy in Patients With Atrial Fibrillation treated With oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation. 2018; 138: 527–536. DoI: 10.1161/CIRCULATIONAHA.118.034722.
3. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal. 2017; 0: 1–48.
4. Rubboli A., Halperin J. L., Airaksinen K.E. et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Annmed. 2008; 40 (6): 428–36. doi: 10.1080/07853890802089786.
5. Dewilde W. J., Oirbans T., Verheugt F. W. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013 Mar 30; 381 (9872): 1107–15. doi: 10.1016/s0140–6736 (12) 62177–1.